A chemotherapy‐free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma

G.S. is a consultant and member of a speaker bureau for Beigene, Kite Pharma. T.J.P. provides consulting for AbbVie, ADC Therapeutics, AstraZeneca, BMS, Bayer, BeiGene, Eli Lilly, Epizyme, Genentech, Genmab, Gilead, Incyte, Pharmacyclics, Regeneron, Seattle Genetics and Xencor; is a member of a scientific committee for Epizyme, Genentech, Genmab, and Merck; and conducts research for Bayer, BMS and AbbVie. A.V.D. has received consulting fees from Abbvie, AstraZeneca, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Janssen, Lilly Oncology, MEI Pharma, Merck, Morphosys and Nurix, and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma and Nurix. The other authors declare no competing financial interests. For original data and protocol, contact Dr. Alexey Danilov. Appendix S1. Figure S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.